Osteosarcoma is the most frequent type of primary bone tumors among children and adolescents. During the past years, little progress has been made regarding prognosis of osteosarcoma patients, especially for those with metastatic disease. Genomic instability and gene alterations are common, but current data do not reveal a consistent and repeatable pattern of osteosarcoma development, thus paralleling the tumor's high heterogeneity. Critical signal transduction pathways have been implicated in osteosarcoma pathobiology and are being evaluated as therapeutic targets, including receptor activator for nuclear factor-κB (RANK), Wnt, Notch, phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin, and mechanotransduction pathways. Herein, we recapitulate and discuss recent advances in the context of molecular mechanisms and signaling networks that contribute to osteosarcoma progression and metastasis, towards patient-tailored and novel-targeted treatments.
IsakoffMSBielackSSMeltzerPGorlickR. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol2015; 33: 3029–35.
2.
KansaraMTengMWSmythMJThomasDM. Translational biology of osteosarcoma. Nat Rev Cancer2014; 14: 722–35.
3.
PapachristouDJPapavassiliouAG. Osteosarcoma and chondrosarcoma: new signaling pathways as targets for novel therapeutic interventions. Int J Biochem Cell Biol2007; 39: 857–62.
4.
PapachristouDJBasdraEKPapavassiliouAG. Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev2012; 32: 611–36.
5.
BroadheadMLClarkJCMyersDEDassCRChoongPF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma2011; 2011: 959248–959248.
6.
SavageSAMirabelloLWangZGastier-FosterJMGorlickRKhannaCFlanaganAMTiraboscoRAndrulisILWunderJSGokgozNPatiño-GarciaASierrasesúmagaLLecandaFKurucuNIlhanIESariNSerraMHattingerCPicciPSpectorLGBarkauskasDAMarinaNde ToledoSRPetrilliASAmaryMFHalaiDThomasDMDouglassCMeltzerPSJacobsKChungCCBerndtSIPurdueMPCaporasoNETuckerMRothmanNLandiMTSilvermanDTKraftPHunterDJMalatsNKogevinasMWacholderSTroisiRHelmanLFraumeniJFJrYeagerMHooverRNChanockSJ. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet2013; 45: 799–803.
7.
ChenXBahramiAPappoAEastonJDaltonJHedlundEEllisonDShurtleffSWuGWeiLParkerMRuschMNagahawattePWuJMaoSBoggsKMulderHYergeauDLuCDingLEdmonsonMQuCWangJLiYNavidFDawNCMardisERWilsonRKDowningJRZhangJDyerMA. St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep2014; 7: 104–12.
8.
LamoureuxFRichardPWittrantYBattagliaSPiletPTrichetVBlanchardFGouinFPitardBHeymannDRediniF. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res2007; 67: 7308–18.
9.
MolyneuxSDDi GrappaMABeristainAGMcKeeTDWaiDHPaderovaJKashyapMHuPMaiuriTNaralaSRStambolicVSquireJPenningerJSanchezOTricheTJWoodGAKirschnerLSKhokhaR. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest2010; 120: 3310–25.
10.
MoriKLe GoffBBerreurMRietAMoreauABlanchardFChevalierCGuisle-MarsollierILégerJGuicheuxJMassonMGouinFRédiniFHeymannD. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol2007; 211: 555–62.
11.
WittrantYLamoureuxFMoriKRietAKamijoAHeymannDRediniF. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol2006; 28: 261–9.
12.
LeeJAJungJSKimDHLimJSKimMSKongCBSongWSChoWHJeonDGLeeSYKohJS. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer2011; 56: 738–43.
13.
BeristainAGNaralaSRDi GrappaMAKhokhaR. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci2012; 125: 943–55.
Bago-HorvathZSchmidKRosslerFNagy-BojarszkyKFunovicsPSulzbacherI. Impact of RANK signalling on survival and chemotherapy response in osteosarcoma. Pathology2014; 46: 411–5.
16.
OhbaTColeHACatesJMSloskyDAHaroHAndoTSchwartzHSSchoeneckerJG. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL. J Bone Miner Res2014; 29: 1431–45.
17.
CathomasRRothermundtCBodeBFuchsBvon MoosRSchwitterM. RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?Oncology2015; 88: 257–60.
18.
CaiYCaiTChenY. Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J Cell Biochem2014; 115: 625–31.
19.
ChenCZhaoMTianAZhangXYaoZMaX. Aberrant activation of Wnt/beta-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget2015; 6: 17570–83.
20.
VijayakumarSLiuGRusIAYaoSChenYAkiriGGrumolatoLAaronsonSA. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/beta-catenin target gene, CDC25A. Cancer Cell2011; 19: 601–12.
21.
ChenKFallenSAbaanHOHayranMGonzalezCWodajoFMacDonaldTToretskyJAUrenA. Wnt10b induces chemotaxis of osteosarcoma and correlates with reduced survival. Pediatr Blood Cancer2008; 51: 349–55.
22.
HoangBHKuboTHealeyJHSowersRMazzaBYangRHuvosAGMeyersPAGorlickR. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer2004; 109: 106–11.
23.
GuoYZiXKoontzZKimAXieJGorlickRHolcombeRFHoangBH. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res2007; 25: 964–71.
24.
HaydonRCDeyrupAIshikawaAHeckRJiangWZhouLFengTKingDChengHBreyerBPeabodyTSimonMAMontagAGHeTC. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer2002; 102: 338–42.
25.
IwayaKOgawaHKurodaMIzumiMIshidaTMukaiK. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis2003; 20: 525–9.
26.
MaYRenYHanEQLiHChenDJacobsJJGitelisSO'KeefeRJKonttinenYTYinGLiTF. Inhibition of the Wnt-beta-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun2013; 431: 274–9.
27.
LinCHGuoYGhaffarSMcQueenPPourmoradyJChristARooneyKJiTEskanderRZiXHoangBH. Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma2013; 2013: 147541–147541.
28.
KansaraMTsangMKodjabachianLSimsNATrivettMKEhrichMDobrovicASlavinJChoongPFSimmonsPJDawidIBThomasDM. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest2009; 119: 837–51.
29.
RubinEMGuoYTuKXieJZiXHoangBH. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther2010; 9: 731–41.
30.
BakerEKTaylorSGupteAChalkAMBhattacharyaSGreenACMartinTJStrbenacDRobinsonMDPurtonLEWalkleyCR. Wnt inhibitory factor 1 (WIF1) is a marker of osteoblastic differentiation stage and is not silenced by DNA methylation in osteosarcoma. Bone2015; 73: 223–32.
31.
ZhaoSKurenbekovaLGaoYRoosACreightonCJRaoPHicksJManTKLauCBrownAMJonesSNLazarAJIngramDLevDDonehowerLAYusteinJT. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene2015; 34: 5069–79.
32.
Martins-NevesSRCorverWEPaiva-OliveiraDIvan den AkkerBEBriaire-de-BruijnIHBovéeJVGomesCMCleton-JansenAM. Osteosarcoma stem cells have active Wnt/beta-catenin and overexpress SOX2 and KLF4. J Cell Physiol2016; 231: 876–86.
33.
Martins-NevesSRPaiva-OliveiraDIWijers-KosterPMAbrunhosaAJFontes-RibeiroCBovéeJVCleton-JansenAMGomesCM. Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/beta-catenin signaling. Cancer Lett2016; 370: 286–95.
34.
LuBJWangYQWeiXJRongLQWeiDYanCMWangDJSunJY. Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma. Mol Med Rep2012; 5: 1033–6.
35.
EnomotoMHayakawaSItsukushimaSRenDYMatsuoMTamadaKOneyamaCOkadaMTakumiTNishitaMMinamiY. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling. Oncogene2009; 28: 3197–208.
36.
ZhangAHeSSunXDingLBaoXWangN. Wnt5a promotes migration of human osteosarcoma cells by triggering a phosphatidylinositol-3 kinase/Akt signals. Cancer Cell Int2014; 14: 15–15.
37.
SulzbacherIBirnerPDominkusMPichlhoferBMazalPR. Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome. Pathology2010; 42: 664–8.
38.
SulzbacherIBirnerPTriebKTraxlerMLangSChottA. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol2003; 16: 66–71.
39.
YuXWWuTYYiXRenWPZhouZBSunYQZhangCQ. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol2014; 35: 155–60.
40.
LiuYMaYHSunZZRuiYJYinQDSongSWeiXMLiuJLiuXGHuKJ. Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies. Tumour Biol2014; 35: 8939–43.
41.
PollakMNPolychronakosCRichardM. Insulin-like growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst1990; 82: 301–5.
42.
SegalinyAITellez-GabrielMHeymannMFHeymannD. Receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol2015; 4: 1–12.
43.
PapachristouDJGkretsiVRaoUNPapachristouGIPapaefthymiouOABasdraEKWuCPapavassiliouAG. Expression of integrin-linked kinase and its binding partners in chondrosarcoma: association with prognostic significance. Eur J Cancer2008; 44: 2518–25.
44.
RheeSHHanILeeMRChoHSOhJHKimHS. Role of integrin-linked kinase in osteosarcoma progression. J Orthop Res2013; 31: 1668–75.
45.
GargalionisANKaramouzisMVPapavassiliouAG. The molecular rationale of Src inhibition in colorectal carcinomas. Int J Cancer2014; 134: 2019–29.
46.
ChenQZhouZShanLZengHHuaYCaiZ. The importance of Src signaling in sarcoma. Oncol Lett2015; 10: 17–22.
47.
ShorACKeschmanEALeeFYMuro-CachoCLetsonGDTrentJCPledgerWJJoveR. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res2007; 67: 2800–8.
48.
SpreaficoASchenoneSSerchiTOrlandiniMAngelucciAMagriniDBernardiniGCollodelGDi StefanoATintoriCBolognaMManettiFBottaMSantucciA. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB J2008; 22: 1560–71.
49.
HingoraniPZhangWGorlickRKolbEA. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin Cancer Res2009; 15: 3416–22.
50.
ChandhanayingyongCKimYStaplesJRHahnCLeeFY. MAPK/ERK Signaling in osteosarcomas, ewing sarcomas and chondrosarcomas: therapeutic implications and future directions. Sarcoma2012; 2012: 404810–404810.
51.
PapachristouDJBatistatouASykiotisGPVarakisIPapavassiliouAG. Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone2003; 32: 364–71.
52.
PapachristouDJPapachristouGIPapaefthimiouOAAgnantisNJBasdraEKPapavassiliouAG. The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up- regulation of VEGF. Histopathology2005; 47: 565–74.
53.
WangZQLiangJSchellanderKWagnerEFGrigoriadisAE. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res1995; 55: 6244–51.
54.
LeanerVDChickJFDonningerHLinniolaIMendozaAKhannaCBirrerMJ. Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. Am J Pathol2009; 174: 265–75.
55.
ZhangJYuXHYanYGWangCWangWJ. PI3K/Akt signaling in osteosarcoma. Clin Chim Acta2015; 444: 182–92.
56.
PerryJAKiezunATonziPVan AllenEMCarterSLBacaSCCowleyGSBhattASRheinbayEPedamalluCSHelmanETaylor-WeinerAMcKennaADeLucaDSLawrenceMSAmbrogioLSougnezCSivachenkoAWalenskyLDWagleNMoraJde TorresCLavarinoCDos Santos AguiarSYunesJABrandaliseSRMercado-CelisGEMelendez-ZajglaJCárdenas-CardósRVelasco-HidalgoLRobertsCWGarrawayLARodriguez-GalindoCGabrielSBLanderESGolubTROrkinSHGetzGJanewayKA. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA2014; 111: E5564–73.
57.
MoriarityBSOttoGMRahrmannEPRatheSKWolfNKWegMTManloveLALaRueRSTemizNAMolyneuxSDChoiKHollyKJSarverALScottMCForsterCLModianoJFKhannaCHewittSMKhokhaRYangYGorlickRDyerMALargaespadaDA. A sleeping beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis. Nat Genet2015; 47: 615–24.
58.
KuijjerMLvan den AkkerBEHilhorstRMommersteegMBuddinghEPSerraMBürgerHHogendoornPCCleton-JansenAM. Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy. BMC Med Genomics2014; 7: 4–4.
59.
ZhaoSLuNChaiYYuX. Rapamycin inhibits tumor growth of human osteosarcomas. J BUON2015; 20: 588–94.
60.
GupteABakerEKWanSSStewartELohAShelatAAGouldCMChalkAMTaylorSLackovicKKarlströmÅMutsaersAJDesaiJMadhamshettiwarPBZannettinoACBurnsCHuangDCDyerMASimpsonKJWalkleyCR. Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma. Clin Cancer Res2015; 21: 3216–29.
61.
PignochinoYDell'AglioCBasiricòMCapozziFSosterMMarchiòSBrunoSGammaitoniLSangioloDTorchiaroED'AmbrosioLFagioliFFerrariSAlberghiniMPicciPAgliettaMGrignaniG. The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res2013; 19: 2117–31.
62.
GrignaniGPalmeriniEFerraresiVD'AmbrosioLBertulliRAsafteiSDTamburiniAPignochinoYSangioloDMarchesiECapozziFBiaginiRGambarottiMFagioliFCasaliPGPicciPFerrariSAgliettaM. Italian Sarcoma Group. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol2015; 16: 98–107.
63.
HughesDP. How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res2009; 152: 479–96.
64.
EnginFBertinTMaOJiangMMWangLSuttonREDonehowerLALeeB. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet2009; 18: 1464–70.
65.
TanakaMSetoguchiTHirotsuMGaoHSasakiHMatsunoshitaYKomiyaS. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br J Cancer2009; 100: 1957–65.
66.
TaoJJiangMMJiangLSalvoJSZengHCDawsonBBertinTKRaoPHChenRDonehowerLAGannonFLeeBH. Notch activation as a driver of osteogenic sarcoma. Cancer Cell2014; 26: 390–401.
67.
McManusMMWeissKRHughesDP. Understanding the role of Notch in osteosarcoma. Adv Exp Med Biol2014; 804: 67–92.
68.
NguyenAScottMADrySMJamesAW. Roles of bone morphogenetic protein signaling in osteosarcoma. Int Orthop2014; 38: 2313–22.
69.
GobbiGSangiorgiLLenziLCasadeiRCanaiderSStrippoliPLucarelliEGhediniIDonatiDFabbriNWarzechaJYeoungCHelmanLJPicciPCarinciP. Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol2002; 20: 143–7.
70.
YoshikawaHTakaokaKHamadaHOnoK. Clinical significance of bone morphogenetic activity in osteosarcoma. A study of 20 cases. Cancer1985; 56: 1682–7.
71.
YoshikawaHTakaokaKMasuharaKOnoKSakamotoY. Prognostic significance of bone morphogenetic activity in osteosarcoma tissue. Cancer1988; 61: 569–73.
72.
GuoWGorlickRLadanyiMMeyersPAHuvosAGBertinoJRHealeyJH. Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop Relat Res1999; 365: 175–83.
73.
MohsenyABCaiYKuijjerMXiaoWvan den AkkerBde AndreaCEJacobsRten DijkePHogendoornPCCleton-JansenAM. The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. Eur J Cancer2012; 48: 3429–38.
74.
SpyropoulouAKaramesinisKBasdraEK. Mechanotransduction pathways in bone pathobiology. Biochim Biophys Acta2015; 1852: 1700–8.
75.
ChenYPasaperaAMKoretskyAPWatermanCM. Orientation-specific responses to sustained uniaxial stretching in focal adhesion growth and turnover. Proc Natl Acad Sci USA2013; 110: E2352–61.
76.
ZhengLZhangDZhangYWenYWangY. mTOR signal transduction pathways contribute to TN-C FNIII A1 overexpression by mechanical stress in osteosarcoma cells. Mol Cells2014; 37: 118–25.
77.
WangYManYDingYMaBQiuXFanQZhengL. Mechanical strain and growth factors regulate expression of tenascin-C by OS cells additively. Oncol Res2013; 20: 509–16.
78.
LienSCChangSFLeePLWeiSYChangMDChangJYChiuJJ. Mechanical regulation of cancer cell apoptosis and autophagy: roles of bone morphogenetic protein receptor, Smad1/5, and p38 MAPK. Biochim Biophys Acta2013; 1833: 3124–33.
79.
HsuHJLeeCFLockeAVanderzylSQKaunasR. Stretch-induced stress fiber remodeling and the activations of JNK and ERK depend on mechanical strain rate, but not FAK. PLoS One2010; 5: e12470–e12470.
80.
QiuNZhouHXiaoZ. Downregulation of PKD1 by shRNA results in defective osteogenic differentiation via cAMP/PKA pathway in human MG-63 cells. J Cell Biochem2012; 113: 967–76.
81.
DalagiorgouGPiperiCGeorgopoulouUAdamopoulosCBasdraEKPapavassiliouAG. Mechanical stimulation of polycystin-1 induces human osteoblastic gene expression via potentiation of the calcineurin/NFAT signaling axis. Cell Mol Life Sci2013; 70: 167–80.
82.
GargalionisANKorkolopoulouPFarmakiEPiperiCDalagiorgouGAdamopoulosCLevidouGSaettaAFragkouPTsioliPKiarisHZizi-SerbetzoglouAKaravokyrosIPapavassiliouKATsavarisNPatsourisEBasdraEKPapavassiliouAG. Polycystin-1 and polycystin-2 are involved in the acquisition of aggressive phenotypes in colorectal cancer. Int J Cancer2015; 136: 1515–27.
83.
GargalionisANPapavassiliouKABasdraEKPapavassiliouAG. Polycystins: mechanosensors with diagnostic and prognostic potential in cancer. Trends Mol Med2016; 22: 7–9.
84.
HuangYWChangSJI-Chen HarnHHuangHTLinHHShenMRTangMJChiuWT. Mechanosensitive store-operated calcium entry regulates the formation of cell polarity. J Cell Physiol2015; 230: 2086–97.
85.
ZhouWHaoMDuXChenKWangGYangJ. Advances in targeted therapy for osteosarcoma. Discov Med2014; 17: 301–7.
UeharaTFujiwaraTTakedaKKunisadaTOzakiTUdonoH. Immunotherapy for Bone and Soft Tissue Sarcomas. Biomed Res Int2015; 2015: 820813–820813.
88.
BrahmerJRTykodiSSChowLQHwuWJTopalianSLHwuPDrakeCGCamachoLHKauhJOdunsiKPitotHCHamidOBhatiaSMartinsREatonKChenSSalayTMAlaparthySGrossoJFKormanAJParkerSMAgrawalSGoldbergSMPardollDMGuptaAWiggintonJM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med2012; 366: 2455–65.
89.
KantoffPWHiganoCSShoreNDBergerERSmallEJPensonDFRedfernCHFerrariACDreicerRSimsRBXuYFrohlichMWSchellhammerPF. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med2010; 363: 411–22.
90.
LussierDMO'NeillLNievesLMMcAfeeMSHolechekSACollinsAWDickmanPJacobsenJHingoraniPBlattmanJN. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother2015; 38: 96–106.
